2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.
It's easy to be bullish about Argenx.
Overview
Argenx (NASDAQ: ARGX) has been a solid winner for investors over the last 12 months, with its shares rising by roughly 30%. Wall Street thinks that the biotech stock can go even higher. The consensus one-year price target for Argenx reflects a potential upside of around 20%.
Two analysts, though, are even more bullish. Wells Fargo's (NYSE: WFC) Derek Archila and UBS' (NYSE: UBS) Xian Deng predict that Argenx's share price can soar more than 40% over the next 12 months. Here's why they're probably right.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.